# embecta to Report Fiscal Fourth Quarter and Full Year 2026 Financial Results

- Published: 2026-11-20
- Author: [Embecta Corp.](https://healthcarenews.io/news/embecta-to-report-fiscal-fourth-quarter-and-full-year-2026-financial-results.md)
- Press release: [Read the release](<https://www.globenewswire.com/news-release/2026/11/20/3407758/0/en/embecta-to-report-fiscal-fourth-quarter-and-full-year-2026-financial-results.html>)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/embecta-to-report-fiscal-fourth-quarter-and-full-year-2026-financial-results/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

PARSIPPANY, N.J., Nov. 20, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2026 financial results, provide an operational update, including preliminary fiscal year 2027 financial guidance, and host a question and answer session at 8:00 a.m. Eastern Time (ET) on Tuesday, November 24, 2026.

Those who would like to participate may access the live webcast <a href="https://www.globenewswire.com/Tracker?data=x9QRaVvrLxwF9CQoA44SMk_Pwi63Tw7POFdnf37a5takRR51K0YGW0Gb2Da0zdXt-1NwYhYGfRCgG2ErONwabXUq_ssFpE6lWElFRfVrINV6JqzUMjR7gIh3KpG84WDD0jQJviponJX0iKgQJppW91DALuHssKVNuQGAnfaLru9U_NjpR5xPz5oUdrnlK8f7u-7tcKXGI4yVIlpFL-S0wIT0x_noTw5mb2BftMMWVw-D2mUt37oKgTL_IHpH_Pzq0vNm5wo22Pp4uXUrc1ed0gFjcbnC2hptMsejEMm9ovQ641Fjmb6l_Gqgdh8FwujZ1-jBoiv2AcslFW0hyn0Lz1RCK0VDzRNy_xNPQobr3OYk8bgO0b9p8jNv5jon2QPDRmw6-D6fO_Yv37qlkdrUf2roKIzYhZpoSjRCQKn7a0FEAOlNpXBAeU8NlE4Vrr3VjdyIoAJtQw6_XDlSk3mUK6C7MOtXhNCrTuZHK7wga3wZn5dWLJgQWajDhIsEGU7fchEJZuhpU6jR95xrDoIhntuwd2i1Io3b_P16z_bBcKHJyFYvMFT1F9_8Ck5odN49vytauwibOkH9me3M-DCLzt6A0D2VS6hWBulgnVj2LQvcwMimaTj0ZQbXcRgAUHjtejbJpXXPeuuscu8dEuiwGB_TcW7SThgRgqbQEF8sMVNw_KHFUCOFpDleYDvnkoZ6O2MnDlWEgMFnp3uThd7JgHK7ZR116HAw3xm9pYhk5HxRNCKBcT6NPPufl_i5oB2z20Cq94fC_a2yA6uH8pmbSBIU0tAiX9n0EtwdmqtJDKY08jsupLiSyEOtHz5nPpHpB0RWcW84TzaCXXaRszJHO47A0sufPjSeTbJgixvHXZo=" rel="nofollow">here</a>, or access the teleconference <a href="https://www.globenewswire.com/Tracker?data=x9QRaVvrLxwF9CQoA44SMl1KSTCrGKEmbWqXBRadQl-eSWMZJhC4wuj8UMNoYjXSLGo-DKWOMaK0s6rQ2Gi-IYi7Jw3D_lgs8e8sRIWXZlNU-r0VriJ1ZJRI1u-BRF1bf4XbaqvtEsK-UefZuctpRgVhBYGNYXMgLHQYteQsriY=" rel="nofollow">here</a>. The live webcast can also be accessed via the company's website at <a href="https://www.globenewswire.com/Tracker?data=_j31A_qxW8uPzWDmwRAHu781zbnf9yn6GECSxXLOfQLNpRqKn1gzsAoNTuNEpFpoOy2wQSIY4HKEwY3Ji-15kYS3egcJaCDklhR-uDN3TJs=" rel="nofollow">investors.embecta.com</a>.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on November 24, 2026, via the embecta investor relations website and archived on the website for one year.

**About embecta  
**embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,500 employees around the globe. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=9Qkpks78O2Lt-ZmiVEbvI5FvbeYelw0CFUNPWrNcIcKM9fQHUT8b8Ld_FO_9N3DJZR571iwFHx9hAFKk3kVFK75vUItj3-h4YwdHSkIiC9HJ7eQrfK51N_kuA7H179CX7yO0nBtl_bgiHFgHMyKxQo22xtg_L2z8BoT_1ppnYP7Ib2R2YMKsf5NnQ9XF1KFdWjqo5Sr51tY2Gz09rx3uPgCIbYoo9Je15yhtSUN6mfFoLNZIRXCEeDM0fotgXmFgGvdWFM_tWV0a2POEdbzNn4nuXPzp_c3Ym47nk6-Qs2dXvzHlJKmJc502JFT9CnaXE_gHTfqP_2-xe8QiwfZHibBiTvim_1rBZuvDRMGCGQYq1gCw1NE2POEwhu_6h-u1FjNjR7bM3d6_Oy3tzXCCVCjK7vjjaFg8wLhNW2h6wV9kAcGlBaCeNOfBpbFaubHQNNAyHspKeZFWMxfOzf96NRihT6MR5jbCKx6-21ulqqisPwKPy-fIo7bXOjfa8M3uxrR-9OAQ5kQMce1f_dgLBfL-4s7oqZtv31V-0_1YSs0ZdwU-Oly-2zK4X8TRGcjRW538fX7_kOgEtZ_DTU-dTzNx7FFpQe_TanTHvBgf9PcYxDScH4_6NWDRbfisshk2oAbPS4vYg7adBEtS9IQ37ylohIBHhkMDVFGpst00VOawkADe-b6ImfjdKxNX2idQsdRL1r3_rzc_WSr9dybJjmjpukQN1PouT0gsMFztdaM=" rel="nofollow">embecta.com</a> or follow our social channels on <a href="https://www.globenewswire.com/Tracker?data=WqPdQihyKcL2eD6wPtgVCdvVxlgVGCt2spOCyNYQ_HUc58UPzhypKwbkcndMFkUPSpzQnEIQWz6PbthbgIF__SSDLtVbyEzC-3Wfldd226qZ9zHEj7ahkFqBTcLIaX-kfIJSTKAFPsyghfGeen10ecw5j0g3d6oxTDG_AY2UivKUN5TGy0OYrHBG8uSH4ZHhe2YtUpu4vggvcigOdHzMVCMbG3cWn42Vp6ba5xfP4TK2Df0VxSoHkBBqq2Rw_XPHyAM7qbM5Wz5uLboBSS-6lHXbeA9dJzscVEb8t8JJAcgwrJ9qf7b7Qeo7siry4wolNQ44oBkjRbAcyOil8IZhgXGKqh5wErgVwjFqfpumiudXl-tCvz__DgthavBCFHML36RaXkgXNdwoux-CDvybZRO-8BNJiIrz9s_GeKYC27FecDLz1llGiVkrkNt4BuzRbr85xbX-6EnwGnxemggmTOV7gln93Abcilp-5Q7y1OUW7QpnNSZh-bYxRG74HMdZD41OQtbhCYiDSpnffTMuBHPRuHN6RsnLDDLKIAJrbtqXGsolGLnJ7Mm0AXfubScYdAwXJwe08qB2hY4NPTEh_lg7kzoM7fvPEOO1yZH4yv6PaML6hd5pjs_RbwtVcx-KpGxdVkPGX5P4jy0dQUJLVXr-kADSkBuSoqAlxL-1b6-yWixYD_CG0I9NPNkr-U9WqEoDspY5-WW_6q2n2UVSOfa-gJ4VzP891zuwxN2zH4KPnW8ch5ejjiIso1Ei464YOAm_NkADxAeizx4eXZtZbw==" rel="nofollow">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=33ELNE8Rgty0xd7irUXTnhC11di_0rEqDgP3ppEyVEHx4XxW2K1vrhy9bTil3C9IlADnKKhCck1omfU00SvmU_GhMQ8UPHT0aUL8wFEGupa1rvnhtb1g9sZDHVbgvYk7dK-7D54xAzfQtEIezrNYk_7FU70CmM4e6fn9HkOKV52OuFCntpHa98LRUrs-dBiuHOFV5ta0_p74yaYDLIgU9BEHfL1IMYt5M8Ck8su0mEJsHijMEl-eNXuVv7WBiO_5q-nzXW5JcHMbeaHVQ6rccStQZ9RuuA5XjrKwOHtSMWqru6UJvyCFHboozmF5dYtwQQKANDk3dHHh4osne5pV37c1Pxz5sE6YhKs26sQWRj6VqCWaZScdDadY0YxERR9rUlnITH_FOY5KfU9cYEeOKQ_t_bf3zjwFmPvS602MBwqjTouvpjj8QbO756uJ8oTVIXPQiPcXGwMUxT0_uTELU4ZeRXDkiyoI0n1F3aex32EzO_LlyeNQz1uTN-XCijQ_zca4A6VezEVqQfi4jRoZBPJL5lhsgll8Z7KykxHTrmQiXCXjLWgOt4MxcnqkO35bRS-n5ceofBKu4rEpdGKntKvldkESO_jU73d8-Lhixi6clWasbnBVwm7ESvcxvdwIVijTuR_nrff6ol5iIFHrlR4fAJHAGNRVWcI1iA0Wj3xbHaqyi2RiDOpSXeD4WYurowHV0lgkDFWDjrBrzokSRW_UWeX3QSoVQuki1-IQmATTeRYDpUsCgSk5buS95b-J" rel="nofollow">Facebook</a>, and <a href="https://www.globenewswire.com/Tracker?data=ZAVPk68QnqGGOLiHfXd9fgqrvSONjwpn8OJ2pWaVQnZceZF0K-3hlZDhLcBdp_wQQkHYcDN2T_K53Bll8FLzJvDW2NPUPfRsK8TXf_gjSnIQHtyqlecGwTIjblhFZe6ZQkBj_DQ3oaPtb7StUdrBv6GgKZy4bcW4rI6hV7xRnPp3sThGqwQyRcC30skJEiwLIaF6O9Ynp6xvk0eySmvGlCrVmZvw6c1amVCx1nGhsLNxnAiwt8uYx_3vvwi5xyxWEJT_ptot1qcC4Zm9-mWZ0YwA8oyIsobRWoEpMtqjzvbvxmmyr_PNULy7TP9Nt6Vh5EOB17kjLpjWa0cXFYffvYqbZQrAoVv1A9rqolWswTZ1wwfevUhTLC_M1CZOB1hzlz9enDW3JX4k_Dk8zMW1IIRUCXjUq0hC-eNeby03uR6ukpVmvqiwGLhJKJZ1BSJzv9r_tHuWngV8Zb5ugvvXvo8tLSPXw6KVT4Y6YMYXna29SVbKYxK1KmYU5I-M8uqLPS9sZp3fF8DN9sPEBJhl2-nmveti7m_orh7tac8ALLFAjsWB1lQh5SQG9ZzcrBjaleQ3eTWC_DpPAp_W33CVwC5PFGrwwydMm2o_W8EtC-jqpH5NLCjLzj5Dw-_Hrvn4qzxoCckEejrDcf_n6p3mU4JvnmZM26C1KhdNJqdVDJG19QtBk18umjc5e9ACNxjW_1d09ohVnpzVMUpUTsM_fD6hnPJ1ZVHDE2F4ENvWTPQrlPxMko9dN7rxhFjsDlU7" rel="nofollow">Instagram</a>.

<table><tbody><tr><td><strong>Contacts:</strong> </td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>Media&nbsp;</td><td>Investors </td></tr><tr><td>Christian Glazar&nbsp;</td><td>Patricia Gonzalez</td></tr><tr><td>Sr. Director, Corporate Communications&nbsp;</td><td>VP, Corporate FP&amp;A and Investor Relations</td></tr><tr><td>908-821-6922&nbsp;</td><td>862-341-2809</td></tr><tr><td><a href="mailto:media.relations@embecta.com">Contact Media Relations</a>&nbsp;</td><td><a href="mailto:investor.relations@embecta.com">Contact IR</a></td></tr></tbody></table>

  
![](https://ml.globenewswire.com/media/Nzc0NzRhZDktMWI0OS00OWIwLWIwMDQtNTc0NjRkZjFlZDBlLTEyNTYxMjItMjAyNi0xMS0yMC1lbg==/tiny/Embecta-Corp-.png)

## Related

- [Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://healthcarenews.io/news/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.md)
- [Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease](https://healthcarenews.io/news/press-release-sanofis-infilbray-approved-in-the-us-as-the-first-medicine-to-treat-neurolog.md)
- [Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program](https://healthcarenews.io/news/palvella-therapeutics-to-host-webcast-to-introduce-new-qtorin-program.md)
- [Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company](https://healthcarenews.io/news/teva-announces-r-d-leadership-transition-eric-hughes-to-depart-the-company.md)
